How to successfully use the EMA IRIS portal to ensure timely submissions

Submitting your scientific advice (SA), orphan drug designation (ODD) or Innovation Task Force (ITF) consultation to the EMA? Avoid delays with our submission recommendations.

In the EU, 90% of interactions with European Medicines Agency (EMA) must be done through various online platforms, like IRIS, the portal for submitting scientific advice (SA), orphan drug designations (ODD), and Innovation Task Force (ITF) consultations. These submissions must be done at specific times designated by EMA, and any unexpected challenges using the IRIS platform can delay your timeline by a month or more.  

EMA SA, ODD, and ITF are critical regulatory tools offered by EMA to guide companies in their drug development. Alira Health has extensive experience engaging with regulators and supporting companies as they prepare their interactions with EMA, developing scientific advice briefing packs, ITF consultations, and ODD dossiers.  

Publications
Published on:
July 14, 2022
Written by:
Oriane Courbier, Marie-Aude Ohresser
These five recommendations can help you ensure a timely submission. Timeliness alone is not a guarantee for a successful submission—the content of your dossier is essential.
Marie-Aude Ohresser, Pharm.D Vice President, Regulatory Affairs

Preparation is key for these interactions, as well as understanding the submission process.  Once you’ve created your EMA account, here are our recommendations for successful submissions: 

  1. Plan ahead: Register your organization in the Organization Management Service (OMS) portal. If your company is not registered in the OMS portal, you will need to “request a new organization” which can take up to 10 business days.  
  1. Be sure to choose the correct roles in IRIS. Multiple roles can be requested in IRIS. The first person needs to be the IRIS Industry User Admin. This first role is reviewed and approved by the EMA, which can take up to two business days. Other roles can then be requested and approved by your Industry User Admin, including IRIS Industry/Parallel Distribution Manager/Contributor. 
  1. Confirm product substances are registered in the EMA public list of all substances. If you cannot find the appropriate substance(s) in the EMA list of substances, you will need to complete a form and raise a request to include the substance in the Substance Management Service (SMS) database. Any substance(s) in the product must be registered in the EMA SMS database before submission to IRIS. This can take up to 10 business days.
  1. Ensure you have a Research Product Identifier (RPI). An RPI identifies a potential new or previously authorized medicinal product developed for one or more conditions by a single company, or by multiple companies in parallel and under an agreement. If your RPI is not for a single medicinal product, you will need to seek assistance from the ITF or scientific advice office, which takes approximately four business days. 
  1. Get a valid EMA customer account number from the EMA account team. Your EMA account number is a required, unique reference number provided by the EMA for financial matters. If you’re using the IRIS portal for the first time, you’ll need to contact the EMA account team first to get your account number. 
About Alira Health  

The five recommendations we shared above can help you ensure a timely submission. Timeliness alone is not a guarantee for a successful submission—the content of your dossier is essential. We at Alira Health can help you define the right time and content for successful interactions with regulators. Our team’s extensive track record includes over 30 SA, 20 ODD, and 15 ITF and EU Innovation National Offices briefing meetings. 

Abbreviations 
  • EMA: European Medicines Agency 
  • ITF: Innovation Task Force  
  • ODD: Orphan drug designation 
  • OMS: Organization Management Service 
  • RPI: Research Product Identifier 
  • SA: Scientific advice 
  • SMS: Substance Management Service 

Related news

Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Publications July 14, 2022
How to successfully use the EMA IRIS portal to ensure timely submissions
Submitting your scientific advice (SA), orphan drug designation (ODD) or Innovation Task Force (ITF) consultation to the EMA? Avoid delays with our submission recommendations.
European Medicines Agency Orphan Drug Regulatory
Multimedia July 12, 2022
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
MedTech Regulatory
Events June 30, 2022
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
DTx trends Market Access Regulatory
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Multimedia April 13, 2022
U.S. and European Regulatory Strategies for Asian MedTech Startups
This webinar will focus on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific.
MedTech Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.